Cubist Pharmaceuticals to Present at Lazard Capital Markets 6th Annual Healthcare Conference
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Robert
Perez, EVP and COO, will present on Wednesday, November 18, 2009 at 1:45
p.m. Eastern Time at the Lazard Capital Markets 6th Annual
Healthcare Conference at the St Regis Hotel in New York City. This
presentation will include discussion of the company’s business
activities, financial outlook, and current news.
A live webcast of the presentation will be accessible through Cubist’s
website at www.cubist.com
in the Investor Relations Conference Calendar section. The webcast will
be available on Cubist’s website for a period of 30 days after the
presentation.
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on
the research, development, and commercialization of pharmaceutical
products that address unmet medical needs in the acute care environment.
In the U.S., Cubist markets CUBICIN® (daptomycin for
injection), the first antibiotic in a new class of anti-infectives
called lipopeptides. In July 2008, Cubist began promoting MERREM®
I.V. (meropenem for injection) in the United States. MERREM is an
established broad spectrum antibiotic developed by AstraZeneca. The
Cubist product pipeline includes ecallantide, a recombinant human
protein in Phase 2 clinical trials — CONSERV™-1 and CONSERV™-2 — for the
reduction of blood loss during cardiac surgery, and two Phase 1
programs that address unmet medical needs, one in CDAD (Clostridium
difficile-associated diarrhea) and the other in multi-drug resistant
(MDR) Gram-negative infections. In addition, the Company, in
collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a
pre-IND and a Phase 2 program underway in novel treatments for
respiratory syncytial virus infections using Alnylam’s RNA-interference
technology. Cubist is headquartered in Lexington, MA. Additional
information can be found at Cubist’s web site at www.cubist.com.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals,
Inc.
AstraZeneca and MERREM are registered trademarks of the AstraZeneca
group of companies.
(c) 2009 Business Wire, Inc., All rights reserved. All of the news releases and other content contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. Any copying or reproduction (other than for an individual user's personal reference), redistribution, reposting or other transmission or communication is expressly prohibited without prior written permission of Business Wire, Inc
